NovoLet® Acceptance Study Within the Hospital Practise in Indonesia

Novo Nordisk A/S203 enrolled

Overview

This study is conducted in Asia. The aim of this study is to evaluate the overall acceptance of healthcare professionals (nurses and doctors) to the NovoLet® system used in a hospital environment.

Study Type

OBSERVATIONAL

Enrollment

203

Conditions

Diabetes Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2

Interventions

insulin humanDRUG

All subjects were treated with human insulin administered either by using the NovoLet® pre-filled insulin system or the conventional vial and syringe method. Doctors and nurses must personally administer at least 10 insulin doses to each patient under their individual clinical supervision for assessment of the NovoLet® pre-filled insulin system

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Type 1 diabetes * Type 2 diabetes * Likely to be hospitalised and require insulin therapy

Locations (1)

Novo Nordisk Investigational Site

Jakarta, Indonesia

Outcomes

Primary Outcomes

Overall acceptance of the NovoLet® system among healthcare professionals (nurses and doctors)

Secondary Outcomes

Time taken for the healthcare professionals (nurses and doctors) to teach the patient

Incidence of adverse drug reactions

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.